Sublingual immunotherapy in children modulates allergen-induced in vitro expression of cytokine mRNA in PBMC

Allergy: European Journal of Allergy and Clinical Immunology

Volumn 61, Issue 10, 2006, Pages 1184-1190

  Savolainen, J ^a,d   Jacobsen, L ^b   Valovirta, E ^c  

^a UNIVERSITY OF TURKU   (Finland)

^b ALK ABELLÓ   (Denmark)

^c Turku Allergy Center   (Finland)

^d UNIVERSITY OF TURKU   (Finland)

Author keywords

Allergic rhinitis; Regulatory T cell; Specific immunotherapy; Th1 cells; Th2 cells

Indexed keywords

ALLERGEN; ALNUS GLUTINOSA EXTRACT PLUS BETULA VERRUCOSA PLUS CORYLUS AVELLANA; CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 4; INTERLEUKIN 5; MESSENGER RNA; POLLEN EXTRACT; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG;

ADOLESCENT; ALDER; ALLERGIC RHINITIS; ARTICLE; BIRCH; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; FEMALE; HAZELNUT; HUMAN; IMMUNOTHERAPY; IN VITRO STUDY; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RHINOCONJUNCTIVITIS; SUBLINGUAL IMMUNOTHERAPY;

ADMINISTRATION, SUBLINGUAL; ADOLESCENT; ALLERGENS; ALNUS; BETULA; CELLS, CULTURED; CHILD; CHILD, PRESCHOOL; CORYLUS; CYTOKINES; DESENSITIZATION, IMMUNOLOGIC; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HUMANS; IMMUNOTHERAPY; INTERFERON TYPE II; INTERFERON-GAMMA; INTERLEUKIN-10; INTERLEUKIN-4; INTERLEUKIN-5; LEUKOCYTES, MONONUCLEAR; MALE; POLLEN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RHINITIS, ALLERGIC, SEASONAL; RNA, MESSENGER; TIME FACTORS; TRANSFORMING GROWTH FACTOR BETA;

EID: 33748294181     PISSN: 01054538     EISSN: 13989995     Source Type: Journal    
DOI: 10.1111/j.1398-9995.2006.01206.x     Document Type: Article

References (40)

1. Scadding K, Brostoff J. Low dose sublingual therapy in patients with allergic rhinitis due to dust mite. Clin Allergy 1986;16:483-491.
2. Canonica GW, Passalacqua G. Noninjection routes for immunotherapy. J Allergy Clin Immunol 2003;3:191-193.
3. de Waal Malefyt R, Abrams J, Bennett B, Figdor CG, de Vries JE. Interleukin 10 (IL-10) inhibits cytokine synthesis by human monocytes: an autoregulatory role of IL-10 produced by monocytes. J Exp Med 1991;174:1209-1220.
4. Del Prete G, De Carli M, Almerigogna F, Giudizi MG, Biagiotti R, Romagnani S. Human IL-10 is produced by both type 1 helper (Th1) and type 2 helper (Th2) T cell clones and inhibits their antigen-specific proliferation and cytokine production. J Immunol 1993;150:353-360.
5. Moore KM, de Waal Malefyt R, Coffman RL, O'Garra A. Interleukin-10 and interleukin-10 receptor. Annu Rev Immunol 2001;19:683-765.
6. Groux H, Bigler M, de Vries JE, Roncarolo MG. Interleukin-10 induces a long-term antigen-specific anergic state in human CD4+ T-cells. J Exp Med 1996;184:19-29.
7. Pierkes M, Bellinghausen I, Hultsch T, Metz G, Knop J, Saloga J. Decreased release of histamine and sulfidoleukotrienes by human peripheral blood leukocytes after wasp venom immunotherapy is partially due to induction of IL-10 and IFN-gamma production of T cells. J Allergy Clin Immunol 1999;103:326-332.
8. Royer B, Varadaradjalou S, Saas P, Guillosson JJ, Kantelip JP, Arock M. Inhibition of IgE-induced activation of human mast cells by IL-10. Clin Exp Allergy 2001;31:694-704.
9. Letterio JJ, Roberts AB. Regulation of immune responses by TGF-beta. Annu Rev Immunol 1998;16:137-161.
10. Chen Y, Kuchroo VK, Inobe J, Hafler DA, Weiner HL. Regulatory T cell clones induced by oral tolerance: suppression of autoimmune encephalomyelitis. Science 1994;265:1237-1240.
11. Weiner HL. Induction and mechanism of action of transforming growth factor-beta-secreting Th3 regulatory cells. Immunol Rev 2001;182:207-214.
12. + T-cell subset inhibits antigen-specific T-cell responses and prevents colitis. Nature 1997;389:737-742.
13. Read S, Powrie F. CD4(+) regulatory T cells. Curr Opin Immunol 2001;13:644-649.
14. Clutterbuck E, Shields JG, Gorden J, Smith SH, Boyd A, Callard RE et al. Recombinant human interleukin-5 is an eosinophil differentiation factor but has no activity in standard human B cell growth factor assays. Eur J Immunol 1987;17:1743-1750.
15. Durham SR, Ying S, Varney VA, Jacobson MA, Sudderick RM, Mackay IS et al. Grass pollen immunotherapy inhibits allergen-induced infiltration of CD4+ T lymphocytes and eosinophils in the nasal mucosa and increases the number of cells expressing messenger RNA for interferon-gamma. J Allergy Clin Immunol 1996;97:1356-1365.
16. Durham SR, Ying S, Varney VA, Jacobson MR, Sudderick RM, Mackay IS et al. Cytokine messenger RNA expression for IL-3, IL-4, IL-5 and granulocyte/ macrophage-colony-stimulating factor in the nasal mucosa after local allergen provocation: relationship to tissue eosinophilia. J Immunol 1992;148:2390-2394.
17. Wilson DR, Nouri-ARIA KT, Walker SM, Pajno GB, O'Brien F, Jacobson MR et al. Grass pollen immunotherapy: symptomatic improvement correlates with reductions in eosinophils and IL-5 mRNA expression in the nasal mucosa during the pollen season. J Allergy Clin Immunol 2001;107:971-976.
18. Bellinghausen I, Metz G, Enk AH, Christmann S, Knop J, Saloga J. Insect venom immunotherapy induces interleukin-10 production and a Th2 to Th1 shift, and changes surface marker expression in venom-allergic subjects. Eur J Immunol 1997;27:1131-1139.
19. Akdis CA, Blesken T, Akdis M, Wütrich B, Blaser K. Role of interleukin 10 in specific immunotherapy. J Clin Invest 1998;102:98-106.
20. Jutel M, Akdis M, Budak F, Aebischer-Casaulta C, Wrzyszcz M, Blaser K et al. IL-10 and TGF-beta cooperate in the regulatory T cell response to mucosal allergens in normal immunity and specific immunotherapy. Eur J Immunol 2003;33:1205-1214.
21. Francis JN, Till SJ, Durham SR. Induction of IL-10+CD4+CD25+ T cells by grass pollen immunotherapy. J Allergy Clin Immunol 2003;111:1255-1261.
22. Savolainen J, Laaksonen K, Rantio-Lehtimäki A, Terho EO. Increased expression of allergen induced in vitro IL-10 and IL-18 mRNA in PBMC of allergic rhinitis patients after specific immunotherapy. Clin Exp Allergy 2004;34:413-419.
23. Valovirta E, Jacobsen L, Ljorring C, Koivikko A, Savolainen J. Clinical efficacy and safety of sublingual immunotherapy with tree pollen extract in children. Allergy 2006;61:1177-1183.
24. Laaksonen K, Junikka M, Lahesmaa R, Terho EO, Savolainen J. In vitro allergen-induced mRNA expression of signaling lymphocytic activation molecule by PBMC of patients with allergic rhinitis is increased during specific pollen immunotherapy. J Allergy Clin Immunol 2003;112:1171-1177.
25. Ciprandi G, Fenoglio D, Cirillo I, Vizzaccaro A, Ferrera A, Tosca MA et al. Induction of interleukin 10 by sublingual immunotherapy for house dust mites: a preliminary report. Ann Allergy Asthma Immunol 2005;95:38-44.
26. Secrist H, Chelen CJ, Wen J, Marshall JD, Umetsu DT. Allergen immunotherapy decreases interleukin 4 production in CD4+ T cells from allergic individuals. J Exp Med 1993;178:2123-2130.
27. Varney VA, Hamid QA, Gaga M, Ying S, Jacobson M, Frew AJ et al. Influence of grass pollen immunotherapy on cellular infiltration and cytokine mRNA expression during allergen-induced late-phase cutaneous responses. J Clin Invest 1993;92:644-651.
28. Jutel M, Pichler WJ, Skrbic D, Urwyler A, Dahinden C, Muller UR. Bee venom immunotherapy results in decrease of IL-4 and IL-5 and increase of IFN-gamma secretion in specific allergen-stimulated T cell cultures. J Immunol 1995;154:4187-4194.
29. Hamid QA, Schotman E, Jacobson MR, Walker SM, Durham SR. Increases in IL-12 messenger RNA+ cells accompany inhibition of allergen induced late skin responses after successful grass pollen immunotherapy. J Allergy Clin Immunol 1997;99:254-260.
30. Dehlink E, Eiwegger T, Gerstmayr M, Kampl E, Bohle B, Chen KW et al. Absence of systemic immunologic changes during dose build-up phase and early maintenance period in effective specific sublingual immunotherapy in children. Clin Exp Allergy 2006;36:32-39.
31. Holt PG, Vines J, Britten D. Sublingual allergen administration: I. Selective suppression of IgE production in rats with high allergen doses. Clin Allergy 1988;18:229-234.
32. Miller A, Lider O, Roberts AB, Sporn MB. Suppressor T cells generated by oral tolerization to myelin basic protein suppress both in vitro and in vivo immune response by the release of TGFbeta following antigen specific triggering. Proc Natl Acad Sci U S A 1992;89:421-425.
33. Bagnasco M, Mariani G, Passalacqua G, Motta C, Bartolomei M, Falagiani P et al. Absorption and distribution kinetics of the mayor parietaria allergen administered by noninjectable routes to healthy human beings. J Allergy Clin Immunol 1997;100:121-129.
34. Bagnasco M, Passalacqua G, Villa G. Pharmacokinetics of an allergen and a monomeric allergoid for oromucosal immunotherapy in allergic volunteers. Clin Exp Allergy 2001;31:54-60.
35. Cottrez F, Groux H. Regulation of TGF-beta response during T cell activation is modulated by IL-10. J Immunol 2001;167:773-778.
36. Nunes I, Shapiro RL, Rifkin DB. Characterization of latent TGF-beta activation by murine peritoneal macrophages. J Immunol 1995;155:1450-1459.
37. Ippoliti F, De Santis W, Volterrani A, Lenti L, Canitano N, Lucarelli S et al. Immunomodulation during sublingual therapy in allergic children. Pediatr Allergy Immunol 2003;14:216-221.
38. Humbert M, Durham SR, Ying S, Kimmitt P, Barkans J, Assoufi B et al. IL-4 and IL-5 mRNA and protein in bronchial biopsies from pateinst with atopic and nonatopic asthma: evidence against intrinsic asthma being a distinct immunopathologic entity. Am J Respir Crit Care Med 1996;154:1497-1504.
39. Moller C, Dreborg S, Ferdousi HA, Halken S, Host A, Jacobsen L et al. Pollen immunotherapy reduces the development of asthma in children with seasonal rhinoconjunctivitis (the PAT-study). J Allergy Clin Immunol 2002;109:251-256.
40. Passalacqua G, Albano M, Riccio AM, Fregonese L, Puccinelli P, Parmiani S et al. Clinical and immunologic effects of a rush sublingual immunotherapy to parietaria species: a double blind placebo controlled trial. J Allergy Clin Immunol 1999;104:964-968.